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Objectives. This study attempted to determine which lesion 
characteristics are associated with reocclusion by 18 to 36 h. 
Background. Reocclusion of the infarct-related artery after 
successful reperfusion is associated with significant morbidity 
and up to a threefold increase in mortality. 
Methods. Two hundred seventy-eight patients with acute myo- 
cardial infarction were randomized to receive either anisoylated 
plasminogen streptokinase activator complex (APSAC) or recom- 
binant issue-type plasminogen activator (rt-PA) or their combi- 
nation. Culprit arteries were assessed for Thrombolysis n Myo- 
cardial Infarction (TIMI) flow grade, lesion ulceration, thrombus, 
collateral circulation and eccentricity. Minimal lumen diameter, 
percent diameter stenosis and lesion irregularity (power) were 
calculated using quantitative angiography. 
Results. Reocclusion was observed more frequently in arteries 
with TIMI 2 versus TIMI 3 flow (10.4% vs. 2.2%, p = 0.003), in 
ulcerated lesions (10.7% vs. 3.0%, p = 0.009) and in the presence 
of collateral vessels (18.2% vs. 5.6%, p = 0.03). Similar trends 
were observed for eccentric (7.3% vs. 2.3%, p = 0.06) and 
thrombotic (8.4% vs. 3.3%, p = 0.06) lesions. Reocclusion was 
associated with more severe mean percent stenosis (77.9% vs. 
73.9%, p = 0.04). Lesion length, reference segment diameter and 
Fourier measures of lesion irregularity were not associated with 
reocclusion. 
Conclusions. Several simply assessed angiographic variables, 
such as the presence of TIMI grade 2 flow, ulceration, collateral 
vessels and greater percent diameter stenosis at 90 rain after 
thrombolytic therapy, are associated with significantly higher 
rates of infarct-related artery reocclusion by 18 to 36 h and may 
aid in identifying the subset of patients who are at significantly 
higher risk of early reocclusion and who potentially warrant 
further early pharmacologic ormechanical intervention. 
(J Am Coll Cardiol 1995;25:582-9) 
Reocclusion of the infarct-related artery after successful reper- 
fusion remains a major limitation of thrombolysis and is 
associated with significant morbidity and up to a threefold 
increase in mortality (1). Despite pharmacologic therapy given 
to maintain early arterial patency, early thrombotic reocclusion 
still occurs in 5% to 10% of patients before hospital discharge 
and in up to 25% of patients by 3 months (1-4). Reocclusion 
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may be clinically silent, and demographic variables have not 
proved helpful in predicting which patients will develop reoc- 
clusion (1,2). However, there may be lesion-related morpho- 
logic characteristics that predispose to early reocclusion of the 
infarct-related artery, and if such angiographic risk factors 
could be identified, adjunctive pharmacologic or mechanical 
strategies might be applied selectively in this subset of high risk 
patients. 
However, the ability of the initial coronary arteriogram 
obtained immediately after thrombolysis topredict reocclusion 
has met with varying success. Several angiographic studies 
(5-9) have identified either a more severe stenosis or a smaller 
minimal lumen diameter as predictive of a higher risk of 
reocclusion. Additional studies have associated reocclusion 
with either a higher "ulceration index" (10), complex lesion 
morphology (10), delayed coronary flow (11) or intermittent 
coronary patency (12). In contrast, pooled data from patients 
in the TAMI trials (2) failed to identify any angiographic 
predictors of recurrent clinical ischemic events. Furthermore, 
data from the recent Global Utilization of Streptokinase and 
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t-PA for Occluded Arteries (GUSTO) (13,14) trial showed 
that minimal lumen diameter, percent stenosis and lesion 
length and irregularity did not predict angiographic reocclu- 
sion at 5 to 7 days after thrombolysis (13,14). Given the 
conflicting findings of previous tudies, the goal of the current 
study was to determine whether new sophisticated computer- 
assisted quantitative analyses or simple visual characterization 
of infarct-related arteries are predictive of reocclusion by 18 to 
36 h. 
Methods 
Patients. The TIMI 4 trial was a multicenter study con- 
ducted at 18 North American centers (15). Inclusion criteria 
included age -<79 years; ischemic chest pain ->30 rain in 
duration within the previous 6 h; new ST segment elevation 
->0.1 mV in two contiguous leads; or new left bundle branch 
block. Exclusion criteria included administration f recombi- 
nant tissue-type plasminogen activator (rt-PA) for myocardial 
infarction within the previous 2 weeks or treatment with 
anisoylated plasminogen streptokinase activator complex 
(APSAC) or streptokinase ver; chronic left bundle branch 
block; women of childbearing potential; oral anticoagula- 
tion; serious systemic illness; psychological inability to partic- 
ipate; previous participation i TIMI 4; inability to undergo 
cardiac catheterization; past or present bleeding disorder; 
history of cerebrovascular disease; confirmed blood pressure 
> 180/110 mm Hg; severe trauma within the previous 3months; 
operation; or prolonged cardiopulmonary resuscitation within 
the previous 2 weeks. Each participating center's institutional 
review board approved the study, and written informed con- 
sent was obtained from all patients. 
Thrombolytic administration. All patients received 325 mg 
of aspirin and a 5,000-U bolus of intravenous heparin followed 
by the initiation of a 1,000-U/h maintenance infusion. Patients 
were then randomized ina double-blind fashion to receive one 
of three drug regimens (15): APSAC (Eminase or Anis- 
treplase, SmithKline Beecham) (30 U intravenously over 2 to 
5 min); rt-PA (Activase or Alteplase, Genentech) (15-rag bolus 
intravenously followed by 0.75 mg/kg body weight [up to 
50 rag] intravenously over 30 rain, then 0.5 mg/kg [up to 35 rag] 
intravenously over 60 rain); or combination therapy (20 U of 
APSAC intravenously over 2 to 5 rain [67% of usual dose of 
APSAC] and a 15-rag bolus of rt-PA followed by a 30-rain 
infusion of 0.75 mg/kg [up to 50 mg]). This is the standard 
bolus of front-loaded rt-PA but 65% of the standard total dose 
of rt-PA. The intravenous heparin was administered for 96 h 
and adjusted to maintain an activated partial thromboplastin 
time between 1.5 and 2 times control. Aspirin was continued 
throughout the hospital period and discharge. In the open- 
label pilot phase of the trial, each participating center treated 
two patients with combination therapy, as previously de- 
scribed. 
Cardiac catheterization methods. After the administration 
of thrombolytic therapy, patients underwent immediate car- 
diac catheterization. The presumed infarct-related artery was 
studied first. Angiography was performed as soon as possible 
after arrival in the cardiac atheterization laboratory, as well as 
at 60, 75 and 90 rain. In addition to multiple orthogonal views 
of the culprit vessel, the nonculprit vessel was also filmed, and 
left ventriculography was performed at the 90-rain time point. 
Angiography was also repeated at 120 min if an intervention 
was planned for a persistently occluded vessel (although 
patients who underwent rescue percutaneous transluminal 
coronary angioplasty at up to 120 rain were excluded from this 
analysis of reocclusion). By protocol, all patients underwent 
repeat angiography at 18 to 36 h or earlier if recurrent pain and 
ST segment deviation were present. Cardiac catheterization 
conditions at 90 rain were reproduced during repeat coronary 
angiography performed at 18 to 36 h. To minimize potential 
variability in vasomotor tone and hemodynamic variables, 
sublingual nitroglycerin was administered at both time points if 
the systolic blood pressure was >110 mm Hg. The angle and 
skew of the gantry, sequence of standard angiographic views, 
type of contrast agent and cardiac atheterization suite used 
were recorded and reproduced. 
Intravascular sheaths remained in place for angiography to 
be performed at 18 to 36 h and were removed after the 
procedure. For 2 h before sheath removal, the heparin infusion 
was halved and was then returned to its previous infusion rate 
2 h later until 96 h of intravenous heparin was completed after 
study drug administration. 
Quantitative angiographic analysis. Cineangiograms, car- 
diac catheterization log sheets and the qualifying electrocar- 
diograms (ECG) were sent to the Angiographic Core Labora- 
tory at the Beth Israel Hospital, Boston, Massachusetts. 
Cardiac catheterization laboratories atall participating centers 
were certified by the Angiographic Core Laboratory for their 
participation i the study on the basis of demonstrated ability 
to follow the study protocol and obtain images of adequate 
quality in the open-label phase of the trial. All eight cine film 
reviewers had no knowledge of treatment group assignment, 
clinical center interpretation of the angiogram or clinical 
outcome of the patient. To ensure adequate blinding for 
patients enrolled at the Beth Israel Hospital or its satellite 
institution, the cinefitms were sent to an Angiographic Core 
Laboratory at Rhode Island Hospital for coronary flow grading 
and lesion morphology assessment. 
The infarct-related artery was identified by review of the 
qualifying ECG, coronary anatomy and left ventriculogram. 
Initial 90-rain and repeat (18 to 36 h) cinefilms were viewed on 
a cineprojector (SONY, model SME3500). From multiple 
views taken at 90 rain and repeated at angiographic follow-up, 
the optimal single projection was selected that identified the 
initial stenosis in its greatest everity without foreshortening or 
overlapping of branches. Three consecutive frames from the 
same phase of the cardiac cycle (preferably end-diastolic 
frames to minimize motion blur) were chosen for quantitative 
angiographic analysis. A previously described and validated 
automated edge detection algorithm was utilized (16). 
A power spectrum estimation using fast Fourier transform 
of discretely sampled data was obtained for each arterial 
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border independently. Total and average power of the lesion, 
proximal reference segment, distal reference segment and 
segment as a whole were calculated for each arterial border for 
each of the three frames. Data from the two borders in the 
three frames were then averaged. 
Qualitative angiographic analysis: TIMI flow grade assess- 
ment. Only patients with patent vessels (TIMI grade 2 or 3 
flow) at 90 rain were analyzed. TIMI grade flow was deter- 
mined as previously defined (17). Reocclusion was defined as 
either TIMI grade 0 or 1 flow at the time of repeat cardiac 
catheterization. I  addition, the number of cine frames re- 
quired for contrast agent o reach a standardized distal coro- 
nary landmark in the infarct-related vessel (TIMI frame count) 
was counted using an electronic frame counter (18). The 
landmarks selected for the analysis were the distalmost branch 
or "fork" in the left anterior descending, the first branch of the 
right posterolateral artery or the first branch of the most distal 
obtuse marginal coronary artery. 
Thrombus grade in the infarct-related artery was assessed 
visually using the following grading system adapted from the 
TIMI IliA study (19): grade 0 = no cineangiographic charac- 
teristics of thrombus present; grade 1 = possible thrombus 
present (angiography demonstrates characteristics, uch as 
reduced contrast density, haziness, irregular lesion contour or 
a smooth convex "meniscus" at the site of total occlusion 
suggestive but not diagnostic of thrombus); grade 2 = small 
thrombus present (definite thrombus with greatest dimensions 
-<50% vessel diameter); grade 3 = moderate thrombus present 
(definite thrombus but with greatest linear dimension >50% 
but less than two vessel diameters); grade 4 = large thrombus 
present (as in grade 3 but with largest dimension greater than 
or equal to two vessel diameters). Thrombus grades 2to 4 were 
combined to determine the incidence of angiographically 
apparent thrombus. 
To assess collateral circulation to the infarct-related artery 
the non-infarct-related artery was studied at 90 rain (the 
primary end point) in 165 patients in the study and was 
visualized at either 60, 75 or 120 min in the remaining patients. 
Only data from patients tudied at 90 rain are presented. 
Collateral circulation supplying the infarct-related artery was 
assessed visually using the following grading system adapted 
from the TIMI IliA trial (19): grade 0 = no collateral vessels 
present (angiography failed to reveal evidence of collateral 
vessels); grade 1 -- minimal collateral vessels present (evidence 
of minimal to partial filling of the recipient artery); grade 2 = 
well developed collateral vessels (evidence of collateral circu- 
lation with nearly complete to complete filling of the recipient 
artery). Collateral circulation grades 1 and 2 were combined in 
the analyses. 
The infarct-related lesion was visually assessed for ulceration 
using the following grading system: grade 0 = no angiographic 
evidence of ulceration; grade 1 = lesion contains a neck with 
contrast material dissecting under the plaque ither proximally 
or distally; grade 2 = distinct extravascular extravasation of 
contrast material. Ulceration grades 1 and 2 were combined in 
the analyses. The culprit lesion was classified as eccentric if the 
plaque thickness was twice as great on one side as that on the 
other. 
Statistical analysis. All values for continuous variables are 
reported as the mean value + SD. Comparison of selected 
variables between groups was performed with the Pearson 
chi-square test for count data and analysis of variance or a 
Student t tests for continuous data. A step-up multiple logistic 
regression model was developed that included the most pow- 
erful univariate predictor as the first covariate. Each of the 
remaining covariates was entered sequentially to determine 
whether they provided additional independent explanatory 
information. A p value of 0.10 was required for retention i  the 
model. All core laboratory measurements and clinical data 
were incorporated into a central data bank maintained at the 
TIMI 4 coordinating center (Research Triangle Institute). 
Resu l ts  
Baseline characteristics. Of the 416 patients participating 
in the randomized and open-label phase of the trial, 307 
patients (307 [75%] of 410) showed patency of the infarct- 
related artery at 90 rain. Of these 307 patients, 278 (91%) had 
a patent infarct-related artery at 90 rain and subsequently 
underwent repeat angiography at 18 to 36 h (mean [_ SD] age 
59 +_ 11 years, range 28 to 79; 67 women [24%], 211 men 
[76%]). The infarction leading to enrollment was the first 
myocardial infarction in 86% of patients. The location of the 
infarct-related artery was distributed as follows: right coronary 
artery in 48% of patients, left anterior descending coronary 
artery in 37%, left circumflex coronary artery in 14%, a 
saphenous vein graft in 1.1% and left main coronary artery in 
0.4% of patients. 
Angiographic measurements. Fourteen (5.0%) of the 278 
patients with patent arteries experienced reocclusion (TIMI 0 
or 1 flow) by 18 to 36 h; 10 (71%) developed symptoms that 
required early recatheterization and coronary angioplasty; and 
4 (29%) had asymptomatic reocclusion treated by angioplasty 
at the time of routine 18 to 36-h angiographic follow-up. 
Certain visually assessed angiographic variables present on 
the 90-min angiogram were associated with subsequent reoc- 
clusion (Table 1). Thrombolysis n Myocardial Infarction grade 
2 flow was present in 71.4% of patients with reocclusion 
compared with only 32.6% of patients with patent arteries (p = 
0.003). Lesion ulceration was present in 57.1% of lesions that 
reoccluded compared with only 25.4% of lesions that remained 
patent (p : 0.009). Collateral vessels to the infarct-related 
artery were present in 33.3% of lesions that reoccluded 
compared with only 11.8% of lesions that remained patent 
(p = 0.03). Similarly, lesion eccentricity and visually apparent 
thrombus tended to be present more frequently at baseline 
angiography in lesions that went on to reocclude (p = 0.06 for 
both comparisons). Reflecting faster blood flow, the number of 
frames required to opacify the vessel was lower (51.3 + 30.5 
frames) in patients whose infarct-related arteries remained 
patent versus 80.8 + 83.9 frames in patients with reocclusion. 
This finding was not statistically significant (p = 0.35), largely 
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Table 1. Relation of Visually Assessed Baseline Angiographic 
Variables to Reocclusion 
Infarct-Related Artery 
Patent Occluded p Value 
TIMI grade 2 flow 32.6% (86/264) 71.4% (10/'14) 
TIMI grade 3 flow 67.4% (178/264) 28.6% (4/14) 
Ulceration 25.4% (67/264) 57.1% (8/14) 
Collateral vessels 11.8% (18/153) 33.3% (4/12) 
Eccentric lesion 52.6% (139/264) 78.6% (11/14) 
Thrombus 32.9% (87/264) 57.1% (8/14) 
TIMI frame count 51.3 + 30.5 80.8 _+ 83.9 
Lesion location 
LAD 36.5% (96/263) 50.0%. (7,/14) 
LCx 14.4% (38/263) 0.0% (0/14) 
RCA 47.5% (125/263) 50.0% (7/14) 
LMCA 0.4% (1/263) 0.0% (0/14 
Saphenous vein graft 1.1% (3/263) 0.0% (0/14) 
0.003 
0.009 
0.034 
0.058 
0.063 
0.354 
0.574 
Data presented are mean value + SD or percent (number) of patients. 
LAD left anterior descending coronary artery; LCx = left circumflex coronary, 
artery; LMCA - left main coronary artery; RCA = right coronary artery; 
TIMI = Yhrombolysis in Myocardial Infarction. 
as a result of the large variability of these values and because 
only 145 patients were available for analysis in this substudy. 
Infarct-related artery location was not related to frequency of 
reocclusion. 
Figure 1 displays the risk of reocclusion on the basis of the 
presence or absence of the angiographic variable. Patients with 
TIMI  grade 2 (delayed) flow had a reocclusion rate of 10.4%, 
which was greater than the 2.2% rate for patients with TIMI 
grade 3 flow (p = 0.003). Reocclusion occurred in 10.7% of 
patients with versus only 3.0% of those without ulceration (p = 
0.009), in 18.2% of patients with versus only 5.6% of those 
without collateral vessels (p = 0.03), in 7.3% of patients with 
versus 2.3% of those without lesion eccentricity (which trended 
toward statistical significance, p = 0.06) and in 8.4% of 
patients with versus 3.3% of those without angiographically 
apparent hrombus (p -- 0.06). 
In addition, certain quantitative angiographic variables at 
90 rain were related to reocclusion (Table 2). Patients experi- 
Table 2. Relation of Baseline Quantitative Angiographic Variables 
to Infarct-Related Artery Patency 
Infarct-Related Artery 
Patent Occluded p Value 
Percent diameter stenosis 73.9 _+ 9.8 77.9 + 10.6 0,04 
Minimal diameter ( am) 0.86 _+ 0.39 0.75 ± 0.34 0,13 
Reference segment diameter (mm) 3.38 _+ 0.93 3.46 + 0.75 0,45 
Length (ram) 8.9 _+ 3.7 10.5 + 4.4 0.27 
Lesion average power 6.3 _+ 9.9 4.7 + 3.3 0.88 
Lesion total power 2.2 _+ 3.0 2.0 _~ 1.0 0.48 
Whole artery average power 10.7 _+ 17.8 8.6 -+ 8.5 0.53 
Data presented are mean value -+ SD. 
encing reocclusion had a more severe mean percent stenosis 
than did those whose infarct-related arteries remained patent 
(77.9% vs. 73.9%, p = 0.04). There was a similar trend for a 
smaller minimal diameter of arteries experiencing reocclusion 
compared with those that remained patent (0.75 vs. 0.86 ram, 
p = 0.13). Angiographic variables that failed to show any 
association with reocclusion included lesion length, reference 
segment diameter and sophisticated Fourier measures of le- 
sion irregularity, such as the average and total power of the 
lesion or the adjacent reference segment diameter. 
Clinical variables, including gender, race or history of 
previous myocardial infarction, were not associated with early 
reocclusion (Table 3). The age and weight of patients whose 
arteries remained patent and of those experiencing reocclusion 
were similar. 
To analyze the relation between drug assignment and 
reocclusion, patients in the open-label phase of the trial were 
excluded, leaving a total of 252 patients who had patent 
infarct-related arteries at 90 rain and underwent repeat angiog- 
raphy at 18 to 36 h. Twelve (4.8%) of these randomized 
patients experienced reocclusion. Table 3 shows that the 8.8% 
rate of reocclusion in patients treated with rt-PA was signifi- 
cantly higher than the 2.2% reocclusion rate for patients 
treated with APSAC alone or the 1.7% reocclusion rate for 
patients treated with combination therapy (p = 0.04). 
Figure 1. Risk of reocclusion in pres- 20 
ence and absence of five different anglo- 18 
graphic variables. Patients with Throm- -- 
bolysis in Myocardial Infarction (TIMI) ~ 16 
grade 2 (delayed) flow had a reocclusion .~ 1 4 
rate of 10.4% compared with 2.2% for 
patients with TIMI grade 3 flow (p = "~ 12 
0.003). Reocclusion occurred in 10.7% o 10 
of patients with versus only 3.0% of 
those without ulceration (p = 0.009), in o 8 
18.2% of patients with versus only 5.6% °~ ," 6 
of those without collateral vessels (p = 
0.03), in 7.3% of patients with versus ~ 4 
2.3% of patients without lesion eccen- " 2 
tricity (p = 0.06) and in 8.4% of patients 
with versus 3.3% of those without angio- 0 
graphically apparent thrombus (p = 0.06). Ulceration Collaterals Eccentric Thrombus 
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Table 3. Frequency ofReocclusion for Various Clinical Variables 
Frequency of 
Reocclusion p Value 
Treatment 0.04* 
rt-PA 8.8% (9/102) 
APSAC 2.2% (2/91) 
APSAC + rt-PA 1.7% (1/59) 
Gender 0.81 
Female 5.2% (11/211) 
Male 4.5% (3/67) 
Race 0.54 
White 5.6% (12/216) 
Black 0.0% (0/31) 
Hispanic 5.0% (1/20) 
Other 9.1% (1/1l) 
Previous MI 0.98 
Present 5.1% (2/39) 
Absent 5.0% (12/239) 
*p - 0.05 when Activase is compared with Eminase; p - 0.07 when Activase 
is compared with combination therapy. Data presented are percent (number) of 
patients. APSAC anysolated plasminogen streptokinase activator complex; 
MI = myocardial infarction; rt-PA = recombinant tissue-type plasminogen 
activator. 
The most powerful univariate predictor of reocclusion was 
the 90-min TIMI flow grade. When a multiple logistic regres- 
sion model that required ap value of 0.10 for retention in the 
model was developed, only TIMI grade 2 flow (p = 0.006) and 
the presence of lesion ulceration (p = 0.012) were identified as 
independent predictors of reocclusion. There was no correla- 
tion between lesion ulceration and TIMI 2 grade flow (r = 
0.007, p - 0.90). 
Discuss ion  
The notion that certain coronary lesion morphologies are 
associated with subsequent vessel closure is well supported by 
studies of patients with the related syndrome of unstable 
angina, in which it has been shown that intraluminal thrombus 
and lesion eccentricity appear to predispose to the subsequent 
development of vessel occlusion (20-26). In patients with 
myocardial infarction who are treated with thrombolysis, the 
risk of reocclusion or recurrent ischemic events is substantial 
and ranges from 18% to 32% (1,5-9,27-29). Several studies 
have identified lesion morphologies or other angiographic 
features that appear to predict reocclusion or recurrent isch- 
emic events, or both. 
Lesion ulceration. Davies et al. (10) examined the relation 
of several morphologic features of infarct-related lesions to 
reocclusion. An "ulceration index" was calculated as the 
maximal intratesional diameter divided by the minimal adja- 
cent intralesion diameter, and 58% of patients with an ulcer- 
ation index >6 exhibited subsequent clinical instability, 
whereas only 8% of those with an ulceration index <6 expe- 
rienced such adverse vents (p < 0.001) (10). Similarly, in the 
Thrombolysis and Angioplasty in Myocardial Infarction 
(TAMI) 1 trial (11), none of the patients with recurrent 
ischemia had lesions with concentric/hourglass e ion morphol- 
ogy, whereas 44% of those who remained free of clinical events 
did have concentric narrowings (p = 0.016). In the present 
study, lesion ulceration also emerged as a highly significant 
correlate of angiographic reocclusion. Furthermore, it was also 
observed that eccentric lesions tended to be associated with a 
higher ate of reocclusion. 
Other investigators (30) have observed that complex ulcer- 
ated coronary lesions are associated with a large transcardiac 
release of serotonin (5-hydroxytryptamine), which may reflect 
ulceration-induced platelet activation. There are data to 
(31,32) suggest that platelet aggregation within ulcerated 
plaques can lead to both thrombotic occlusion and distal 
embolization. It is also known that patients with unstable 
angina whose angiograms are characterized byirregular lesions 
or the presence of filling defects are more likely to experience 
persistent symptoms or adverse in-hospital clinical outcomes 
(33-35). Thus, the present findings together with previous 
studies uggest that the presence of an ulcerated lesion appears 
to identify a very disrupted and thrombogenic lesion with an 
increased susceptibility to reocclusion. 
Percent stenosis and lesion severity. Thrombolytic studies 
(5-9) involving patients treated with either streptokinase or
APSAC have shown that the presence of a high grade residual 
stenosis is one of the stronger predictors of recurrent ischemia. 
In an early study by Serruys et al. (5), a diameter stenosis 
>58% was present in 17 (63%) of 27 patients who developed 
reocclusion, whereas itwas found in only 2 (6%) of 33 patients 
whose vessels remained patent. Gash et al. (6) found that 5 
(29%) of 17 patients with >75% diameter stenosis reoccluded 
compared with 1 (14%) of 7 patients with less severe narrow- 
ings. Harrison et al. (7) found that a minimal lumen area 
<0.4 mm 2 was present in 7 (54%) of 13 patients experiencing 
reocclusion but that none of the arteries that remained patent 
had a minimal umen area this small. In a study by Badger et 
al. (8), 5 (42%) of 12 patients with a minimal umen diameter 
<0.6 ram, but none of 8 patients with a minimal lumen 
diameter >0.6 ram, developed reocclusion. Most recently in 
the Antithrombotics in the Prevention of Reocclusion in 
Coronary Thrombolysis (APRICOT) study (9), which involved 
300 patients, >90% visual stenosis was an independent pre- 
dictor of reocclusion with an odds ratio of 2.31 (p = 0.006). 
In contrast to the previous tudies that utilized streptoki- 
nase or APSAC, detailed analysis of quantitative and morpho- 
logic features of infarct-related arteries in pooled data from 
the TAMI studies in which rt-PA was administered have failed 
to show any relation of these lesion characteristics and recur- 
rent ischemic events (defined as either reocclusion of the 
infarct-related artery, ischemia requiring emergency coronary 
angioplasty, urgent bypass urgery or cardiac death) (2). This 
led the investigators to conclude that the assessment of lesion 
morphology is not useful in risk stratification because it 
predicts neither ecurrent ischemic events nor the need for 
early revascularization after successful thrombolysis. In the 
present study, both morphologic (ulceration, eccentricity) and 
quantitative measures of lesion severity (percent stenosis) were 
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found to be related to reocclusion. Most of the instances of 
reocclusion occurred after the administration f rt-PA. The 
current study differs from the TAMI studies (2,27-29) in that 
it utilizes angiographicaUy documented reocclusion (not clinical 
events or angiography, or both) as the end point. The present 
study also uses a shorter (18 to 36 h) time interval for follow-up 
rather than the more delayed 7 to 10-day time interval in the 
TAMI trial. Thus, 90-rain lesion characteristics appear to be 
related to the subsequent risk of early vessel reocclusion but 
may be less predictive of later clinical events, some of which 
may or may not be related to infarct vessel reocclusion. This 
difference in the follow-up interval to repeat angiography may 
also explain the disparate results of the present study with 
those of the angiographic substudy of the GUSTO trial in 
which no angiographic predictors of reocclusion were identi- 
fied at 5 to 7 days after thrombolysis (14). 
Fourier analysis of reocelusion. Fourier analysis of lesion 
morphology failed to identify correlates of reocclusion after 
thrombolysis. A previous analysis of vessel irregularity using 
curvature values was successful in distinguishing patients with 
unstable angina versus those without his clinical syndrome 
(36). One of the reasons that the Fourier analysis performed in
this study may not have successfully identified high risk pa- 
tients is that unlysed thrombus may not be angiographically 
apparent or may lie outside the single plane being imaged. 
Averaging data from the two arterial borders may also have 
hampered the ability to detect small differences inthe power of 
the vessels. Visual identification of one of the two lumen 
borders as the "culprit" owing to plaque fissuring, presence of 
thrombus, gross irregularity or eccentricity is not generally 
possible, rendering the selective analysis of a single arterial 
border impossible. 
Thrombolysis in Myocardial Infarction flow grade. Using 
the TIMI flow grading system, several trials (13,18,37-41) have 
documented less favorable outcomes in patients with TIMI 
grade 2 flow versus those with TIMI grade 3 flow. In the 
present study, patients with TIMI grade 2 flow at 90 rain had 
greater than a fourfold higher ate of reocclusion than those 
with normal TIMI grade 3 flow (10.4% vs. 2.2%, p = 0.003). As 
in the present study, the TAMI 1 study (11) showed that 
patients with normal TIMI grade 3 flow tended to experience 
recurrent ischemic events less frequently than patients with 
delayed or TIMI 2 flow (18% vs. 44%). In addition, Grines et 
al. (12) found that intermittent patency in the period immedi- 
ately after thrombolysis associated with reocclusion. 
Slowed flow may promote reocclusion by increasing the 
residence time of thrombogenic blood constituents, thereby 
favoring clot propagation i regions of low shear stress or in 
regions of flow reversal, stagnation or turbulence. In addition 
to the finding that delayed anterograde flow down the vessel is 
associated with reocclusion, the presence of collateral vessels 
was also associated with an increased incidence of reocclusion. 
Lesion eccentricity, increasing lesion severity and presence of 
competitive flow from collateral vessels each might contribute 
rheologically to promote post-stenotic flow reversal and turbu- 
lence, which in turn could facilitate thrombosis or clot propa- 
gation along the trailing edge of the lesion. The tendency 
toward reocclusion in patients with TIMI grade 2 flow may 
explain, at least in part, the increased incidence of adverse 
outcomes that has been observed in these patients (18,37-41). 
Clinical implications. At present, new antithrombotic 
agents aimed at reducing reocclusion are under investigation 
for use in all patients treated with thrombolytic agents (42,43). 
Prolonged infusion of therapeutic heparin or newer antithrom- 
botic agents may decrease reocclusion and allow further im- 
mediate (44) and delayed (45) improvement i  lumen diameter 
after initially successful thrombolysis. However identification 
of patients at increased risk for early reocclusion might allow 
the more selective application of additional mechanical inter- 
vention or antithrombotic herapy (e.g., the antiplatelet anti- 
body 7E3) (46) to only high risk patients. The present study 
shows that certain lesion features at 90 min after thrombolysis 
are associated with an increased risk of subsequent reocclu- 
sion; however, no recommendation can be made regarding the 
optimal management of such patients in the absence of their 
prospective randomization among different adjunctive thera- 
pies (e.g., angioplasty, coronary artery bypass grafting or 
prolonged infusion of an antithrombotic agent). 
Study limitations. There are several imitations of this 
study that should be considered. The number of patients 
experiencing reocclusion at 18 to 36 h was small (14 of 278) 
and represented only -5% of patients with patent arteries at 
90 min. Given the low event rate in this trial and all other 
studies examining this issue, larger future angiographic trials 
would be needed to evaluate further the ability of the 90-rain 
angiogram to predict reocclusion. Data from three thrombo- 
lytic regimens were analyzed together in this study. It is 
possible that the importance of lesion morphology in reocclu- 
sion depends omewhat on the specific thrombolytic or anti- 
thrombotic regimen, or both (9). Finally, these findings were 
limited to patients experiencing early reocclusion (18 to 36 h), 
and the same angiographic features may not be predictive of 
later reocclusion occurring after the first day after thromboly- 
sis, as seen in the GUSTO trial (14). 
Conclusions. Several simply assessed angiographic vari- 
ables, such as the presence of TIMI grade 2 flow, ulceration, 
collateral vessels and greater percent diameter stenosis at 
90 rain after thrombolytic therapy, were associated with a 
significantly higher ate of infarct-related artery reocclusion by 
18 to 36 h. Similar trends were also observed for lesion 
eccentricity and presence of thrombus. Fourier analysis of 
lesion morphology failed to identify any correlates of reocclu- 
sion. These simple visual variables may aid in identifying the 
subset of patients who are at higher isk for reocclusion and 
who may warrant further early pharmacologic or mechanical 
intervention. 
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